CHARLES TOWN, W.Va., Sept. 12 /PRNewswire/ -- ReBuilder Medical Technologies, Inc. today reported to its board of directors that it has expanded its international customer base to include England, Canada, New Zealand and Australia.
"These sales began to come in as a result of soldiers and relatives of Americans who experienced success using the ReBuilder System(R). Through word of mouth and the targeted expansion of our international web outreach we saw an increase in sales from foreign countries." says Daena Carter, CFO for ReBuilder Medical Technologies, Inc. "So a few months ago, we developed our website to accommodate these sales with its related shipping and tariff challenges. Now we advertise in these countries and are receiving a steady flow of customers. I expect that we will now increase sales in 2007 to over $4M. Next year should be even better as we identify additional distributors."
We have shipped to Australia, United Kingdom, Canada, New Zealand, and several other countries. "As a result of the increase in sales from foreign countries we are actively seeking distributors and international representation for our products" states Daena Carter. The International Diabetes Federation estimates that more than 230 million people worldwide now live with diabetes. Neuropathy is known to affect more than 30% of all diabetes sufferers. "As we recruit international partners in these and other countries," says Daena Carter, "we ship to them in bulk and save on shipping charges. In addition, overseas partners can translate the sales materials into their own language, and handle customer service without the translation issues. ReBuilder Medical Technologies, Inc. prides itself on excellent customer service and customers are always more comfortable taking to a customer service representative in their own country, who speaks their own dialect, and understands their own customs and religious variations."
The ReBuilder System(R) is an electronic device that restores nerve function, increases blood flow, cancels pain, and reduces numbness and tingling that sells for $399-$699 retail and is available via the Internet.
Twenty million, eight hundred thousand children and adults, or 7% of the U.S. population suffer from diabetes. Thirty percent of those diagnosed with diabetes will eventually suffer from peripheral neuropathy, pain and numbness in the feet and hands that can lead to complete loss of mobility, gangrene, and eventual amputations. $132 Billion per year is the current cost of treating diabetes, or 1 of every 10 health care dollars spent. Neuropathy sufferers constitute 33% of this market, or 43.56 billion dollars in potential market. ReBuilder Medical Technologies, Inc. is a company in its infancy that has targeted 1% of this market, or $43.5 million dollars in its next two market years, and is on course to meet this goal. Its only primary competition is from drug companies whose therapy has proven less successful and prone to side-effects and addiction.
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc is an emerging medical device manufacturer of innovative technologies founded by world renowned medical device inventor David B. Phillips, Ph.D. ReBuilder Medical Technologies's flagship product is its FDA registered ReBuilder System(R) for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) which focus on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery powered medical product that provides a new non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
ReBuilder Medical also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum pathogen without side effects. The company is currently performing research and development on a number of other products as well.
Dr. Phillips is CEO of ReBuilder Medical Technologies, Inc. located in Charles Town, WV. He is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System for the early detection of breast cancer and the AcuPen which simultaneously detects and balances acupuncture points.
More information on ReBuilder Medical and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
|SOURCE ReBuilder Medical Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved